Claritas Pharmaceuticals logo
CLAS.H logo

Claritas PharmaceuticalsTSXV:CLAS.H Stock Report

Market Cap CA$944.7k
Share Price
n/a
1Yn/a
7D0%
Portfolio Value
View

Claritas Pharmaceuticals, Inc.

TSXV:CLAS.H Stock Report

Market Cap: CA$944.7k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

CLAS.H Stock Overview

A clinical-stage specialty pharmaceutical company, focuses on developing and commercializing therapies for patients with unmet medical needs. More details

CLAS.H fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Claritas Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Claritas Pharmaceuticals
Historical stock prices
Current Share PriceCA$0.025
52 Week HighCA$0.025
52 Week LowCA$0.025
Beta0
1 Month Changen/a
3 Month Changen/a
1 Year Changen/a
3 Year Change-94.68%
5 Year Change-96.88%
Change since IPO-99.86%

Recent News & Updates

Recent updates

Shareholder Returns

CLAS.HCA PharmaceuticalsCA Market
7D0%-5.2%-0.002%
1Yn/a-48.5%17.3%

Return vs Industry: Insufficient data to determine how CLAS.H performed against the Canadian Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how CLAS.H performed against the Canadian Market.

Price Volatility

Is CLAS.H's price volatile compared to industry and market?
CLAS.H volatility
CLAS.H Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement12.2%
Market Average Movement8.5%
10% most volatile stocks in CA Market18.3%
10% least volatile stocks in CA Market3.0%

Stable Share Price: CLAS.H has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine CLAS.H's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2014n/aBob Farrellclaritaspharma.com

Claritas Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing therapies for patients with unmet medical needs. The company was formerly known as Kalytera Therapeutics, Inc. and changed its name to Claritas Pharmaceuticals, Inc. in April 2021. Claritas Pharmaceuticals, Inc. was founded in 2014 and is based in San Rafael, California.

Claritas Pharmaceuticals, Inc. Fundamentals Summary

How do Claritas Pharmaceuticals's earnings and revenue compare to its market cap?
CLAS.H fundamental statistics
Market capCA$944.66k
Earnings (TTM)CA$2.50m
Revenue (TTM)n/a

0.0x

P/E Ratio

0.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CLAS.H income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other Expenses-US$1.80m
EarningsUS$1.81m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did CLAS.H perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/07/30 03:21
End of Day Share Price 2024/07/26 00:00
Earnings2021/09/30
Annual Earnings2020/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Claritas Pharmaceuticals, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Douglas LoeEchelon Wealth Partners Inc.